Drug intelligence / Profile preview

PRG-2302

Development stage: Phase 1
Lead developer: Shenzhen Puruijin Biological Pharmaceutical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PRG-2302 is a chimeric antigen receptor T cell (CAR-T) therapy that targets both CD19 and CD22 antigens. It is being developed for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. The drug consists of autologous T cells engineered to express CARs specific for both CD19 and CD22, which are surface proteins commonly found on malignant B cells. By targeting these antigens, PRG-2302 aims to enhance anti-tumor activity and reduce the risk of antigen escape, a common mechanism of resistance in single-target CAR-T therapies. The developer is Shenzhen Puruijin Biological Pharmaceutical Co., Ltd., with clinical trials currently in early phase 1[1][4][6].

Other names: CD19/CD22 Chimeric Antigen Receptor T Cells

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on PRG-2302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRG-2302.

Explore the full profile